Grant Private Wealth Management Inc Has $410,000 Stock Holdings in Johnson & Johnson $JNJ

Grant Private Wealth Management Inc decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 93.1% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,209 shares of the company’s stock after selling 29,872 shares during the quarter. Grant Private Wealth Management Inc’s holdings in Johnson & Johnson were worth $410,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Clark Asset Management LLC grew its position in shares of Johnson & Johnson by 51.6% in the 2nd quarter. Clark Asset Management LLC now owns 8,884 shares of the company’s stock valued at $1,357,000 after acquiring an additional 3,025 shares during the period. Treasurer of the State of North Carolina lifted its stake in Johnson & Johnson by 8.3% in the 2nd quarter. Treasurer of the State of North Carolina now owns 1,234,945 shares of the company’s stock valued at $188,638,000 after purchasing an additional 94,957 shares during the last quarter. Apexium Financial LP grew its holdings in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company’s stock worth $3,978,000 after purchasing an additional 2,310 shares during the period. Avanza Fonder AB increased its position in Johnson & Johnson by 2.9% during the second quarter. Avanza Fonder AB now owns 234,647 shares of the company’s stock worth $35,842,000 after buying an additional 6,566 shares during the last quarter. Finally, Winnow Wealth LLC bought a new stake in Johnson & Johnson in the second quarter valued at approximately $295,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $210.50 on Thursday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $215.18. The company’s 50 day moving average price is $197.44 and its two-hundred day moving average price is $178.46. The firm has a market cap of $507.14 billion, a PE ratio of 20.32, a PEG ratio of 2.27 and a beta of 0.36. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. The ex-dividend date was Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Analysts Set New Price Targets

Several research analysts have recently commented on JNJ shares. HSBC reiterated a “buy” rating and set a $240.00 target price on shares of Johnson & Johnson in a research note on Wednesday, December 10th. Bank of America upped their price objective on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a report on Monday. JPMorgan Chase & Co. increased their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research report on Tuesday, September 16th. The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 9th. Finally, Morgan Stanley increased their price target on shares of Johnson & Johnson from $190.00 to $197.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $208.85.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.